SCHEMBL4672941

SCHEMBL4672941

O=C(Cc1ccoc1Oc1cccc(C(F)(F)F)c1)C(=O)c1nc[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.38
POLB P06746 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAOB P27338 1/20 0.36
AOC3 Q16853 1/20 0.36
MAPT P10636 2/20 0.36
BRAF P15056 1/20 0.35
KCNA3 P22001 2/20 0.35
KCNA5 P22460 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
GAA P10253 1/20 0.35
P2RY1 P47900 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670852 0.88 ALDH1A1 (0.37) ALDH1A1MAOBAOC3BRAF
SCHEMBL4674896 0.85 LMNA (0.38) KDM4EALDH1A1POLBMAPTBRAF
SCHEMBL4673049 0.85 CYP3A4 (0.35) KDM4EPOLBMAOBAOC3
SCHEMBL4671513 0.85 KDM4E (0.41) KDM4EALDH1A1POLBL3MBTL1MAPT
SCHEMBL4676668 0.85 CES1 (0.33) KDM4EALDH1A1BRAF
SCHEMBL4676764 0.83 KDM4E (0.41) KDM4EALDH1A1POLBL3MBTL1MAOB
SCHEMBL4676932 0.83 KDM4E (0.41) KDM4EALDH1A1POLBL3MBTL1MAOB
SCHEMBL4676489 0.82 KDM4E (0.42) KDM4EALDH1A1POLBL3MBTL1MAPT
SCHEMBL4678501 0.82 KDM4E (0.42) KDM4EALDH1A1POLBL3MBTL1MAPT
SCHEMBL4670990 0.81 SIRT2 (0.35) KDM4EALDH1A1POLBL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDM4E 947/4885ALDH1A1 980/4885POLB 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.